2019 Leveraged Finance Fights Melanoma Event

Wednesday, May 22, 06:00pm - 09:00pm (PDT)

Spotlighted in publications like Forbes, Bloomberg and The New York Times, the Leveraged Finance Fights Melanoma (LFFM) event has become the premier gathering of professionals from the leveraged finance, private equity, and investment communities who come together to fight melanoma, the deadliest form of skin cancer. Some of the most prominent names in the industry —Carl Icahn, Mike Milken, Leon Black, Henry Kravis and Howard Marks—have been featured.

The annual event raises critical funds for melanoma research and awareness on skin cancer prevention. Founded in 2011 by Jeffrey Rowbottom of PSP Investments and Brendan Dillon of UBS—both of whom combatted melanoma— the LFFM event has raised more than $8.6 million that goes directly to research.

Advances in melanoma research supported by MRA have changed the landscape dramatically for patients, with 12 of the 14 treatment options coming to market since the event’s kick-off. These advances have created a ripple effect across the field of oncology. Drugs first approved in melanoma are now being tested in more than 30 cancers.

Add to Calendar 5/22/2019 6:00PM 5/22/2019 9:00PM America/Los_Angeles 2019 Leveraged Finance Fights Melanoma Event Spotlighted in publications like Forbes, Bloomberg and The New York Times, the Leveraged Finance Fights Melanoma (LFFM) event has become the premier gathering of professionals from the leveraged finance, private equity, and investment communities who come together to fight melanoma, the deadliest form of skin cancer. Some of the most prominent names in the industry —Carl Icahn, Mike Milken, Leon Black, Henry Kravis and Howard Marks—have been featured.

The annual event raises critical funds for melanoma research and awareness on skin cancer prevention. Founded in 2011 by Jeffrey Rowbottom of PSP Investments and Brendan Dillon of UBS—both of whom combatted melanoma— the LFFM event has raised more than $8.6 million that goes directly to research.

Advances in melanoma research supported by MRA have changed the landscape dramatically for patients, with 12 of the 14 treatment options coming to market since the event’s kick-off. These advances have created a ripple effect across the field of oncology. Drugs first approved in melanoma are now being tested in more than 30 cancers.
Rockefeller Plaza, New York City Melanoma Research Alliance info@curemelanoma.org false MM/DD/YYYY 2880 axsMHgvDnzhFAoDKBmoJ20028

Wednesday, May 22, 06:00pm - 09:00pm (PDT)

Rockefeller Plaza, New York City

Melanoma Research Alliance, info@curemelanoma.org